182 related articles for article (PubMed ID: 2007317)
1. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
[TBL] [Abstract][Full Text] [Related]
3. S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteers.
Chakraborty BS; Hawes EM; McKay G; Hubbard JW; Korchinski ED; Midha KK; Choc MG; Robinson WT
Drug Metabol Drug Interact; 1988; 6(3-4):425-37. PubMed ID: 3271648
[TBL] [Abstract][Full Text] [Related]
4. Absorption and excretion of thioridazine and mesoridazine in man.
Charalampous KD; Johnson PC; Estevez V
Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
[TBL] [Abstract][Full Text] [Related]
5. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
[No Abstract] [Full Text] [Related]
6. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
[TBL] [Abstract][Full Text] [Related]
7. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
Rao ML; Brown WA; Wagner R
Ther Drug Monit; 1988; 10(2):184-7. PubMed ID: 3381236
[TBL] [Abstract][Full Text] [Related]
8. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
Dahl-Puustinen ML; Lidén A; Alm C; Nordin C; Bertilsson L
Clin Pharmacol Ther; 1989 Jul; 46(1):78-81. PubMed ID: 2743709
[TBL] [Abstract][Full Text] [Related]
9. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
Spina E; Steiner E; Ericsson O; Sjöqvist F
Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat.
Lin G; Hawes EM; McKay G; Korchinski ED; Midha KK
Xenobiotica; 1993 Oct; 23(10):1059-74. PubMed ID: 8259689
[TBL] [Abstract][Full Text] [Related]
11. A pilot of plasma thioridazine and metabolites in chronically treated patients.
Papadopoulos AS; Chand TG; Crammer JL; Lader S
Br J Psychiatry; 1980 Jun; 136():591-6. PubMed ID: 7388266
[TBL] [Abstract][Full Text] [Related]
12. Phenolic metabolites of thioridazine in man.
Papadopoulos AS; Crammer JL; Cowan DA
Xenobiotica; 1985 Apr; 15(4):309-16. PubMed ID: 4024665
[TBL] [Abstract][Full Text] [Related]
13. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
14. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism.
Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW
Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341
[TBL] [Abstract][Full Text] [Related]
15. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
16. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
LLerena A; Berecz R; de la Rubia A; Dorado P
J Psychopharmacol; 2002 Dec; 16(4):361-4. PubMed ID: 12503836
[TBL] [Abstract][Full Text] [Related]
17. Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators.
Davi H; Bonnet JM; Berger Y
Xenobiotica; 1992 Feb; 22(2):171-84. PubMed ID: 1632106
[TBL] [Abstract][Full Text] [Related]
18. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
Steiner E; Spina E
Clin Pharmacol Ther; 1987 Sep; 42(3):278-82. PubMed ID: 3621781
[TBL] [Abstract][Full Text] [Related]
19. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
Eap CB; Souche A; Koeb L; Baumann P
Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
[TBL] [Abstract][Full Text] [Related]
20. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
